{"id":297081,"date":"2026-01-22T05:24:17","date_gmt":"2026-01-22T05:24:17","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/297081\/"},"modified":"2026-01-22T05:24:17","modified_gmt":"2026-01-22T05:24:17","slug":"japans-shionogi-boosts-viiv-stake-in-2-13-billion-deal-as-pfizer-exits","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/297081\/","title":{"rendered":"Japan&#8217;s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits"},"content":{"rendered":"\n<p class=\"yf-vbsvxt\">Jan 20 (Reuters) &#8211; Japan&#8217;s Shionogi &amp; Co said on Tuesday it \u200bwould pay $2.13 billion for new \u200cshares in ViiV Healthcare, its joint \u200cventure with British drugmaker GSK, increasing its stake in the HIV drugmaker to 21.7% as U.S. drugmaker \u2060Pfizer exits \u200cits 11.7% shareholding.<\/p>\n<p class=\"yf-vbsvxt\">Under the agreement, Pfizer will receive $1.88 billion \u200dfor its 11.7% holding, and GSK will get a special dividend of $250 \u200bmillion as ViiV cancels the \u200cU.S. drugmaker&#8217;s shares.<\/p>\n<p class=\"yf-vbsvxt\">GSK will retain its 78.3% majority stake in ViiV Healthcare. The British firm established ViiV Healthcare with Pfizer in \u20602009, with Shionogi \u200bjoining as a shareholder \u200bin 2012.<\/p>\n<p class=\"yf-vbsvxt\">The deal streamlines ownership of ViiV Healthcare at \u200da time \u2060when the company is advancing a pipeline of long-acting injectable \u2060HIV treatments and prevention medicines.<\/p>\n<p class=\"yf-vbsvxt\">(Reporting by \u200cYadarisa Shabong in Bengaluru; Editing \u200cby Rashmi Aich)<\/p>\n","protected":false},"excerpt":{"rendered":"Jan 20 (Reuters) &#8211; Japan&#8217;s Shionogi &amp; Co said on Tuesday it \u200bwould pay $2.13 billion for new&hellip;\n","protected":false},"author":2,"featured_media":297082,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[18,135,475,474,19,17,386,93268,147360,4765,147359,147361,147358],"class_list":{"0":"post-297081","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-eire","9":"tag-health","10":"tag-health-care","11":"tag-healthcare","12":"tag-ie","13":"tag-ireland","14":"tag-japan","15":"tag-joint-venture","16":"tag-majority-stake","17":"tag-pfizer","18":"tag-shionogi","19":"tag-viiv","20":"tag-viiv-healthcare"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115937087578685177","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/297081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=297081"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/297081\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/297082"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=297081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=297081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=297081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}